SEC Form 4 · accession 0001177648-18-000038
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tim Ocain
Officer — Senior Vice President
Period of report
Oct 1, 2018
Accepted (ET)
Oct 2, 2018 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 1, 2018 | M | 15,000 | $19.98 | A | 21,127 | D | |
| Common Stock | Oct 1, 2018 | M | 10,000 | $32.27 | A | 31,127 | D | |
| Common StockF2 | Oct 1, 2018 | S | 3,500 | $82.0406 | D | 27,627 | D | |
| Common StockF3 | Oct 1, 2018 | S | 6,219 | $83.4744 | D | 21,408 | D | |
| Common StockF4 | Oct 1, 2018 | S | 14,677 | $84.0167 | D | 6,731 | D | |
| Common StockF5 | Oct 1, 2018 | S | 604 | $85.2995 | D | 6,127 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $19.98 | Oct 1, 2018 | M | 15,000 | D | — | Oct 29, 2023 | Common Stock | 15,000 | 0 | D |
| Stock Option (Right to Buy)F6 | $32.27 | Oct 1, 2018 | M | 10,000 | D | — | Jan 30, 2024 | Common Stock | 10,000 | 60,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $81.84 to $82.21, inclusive.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $82.77 to $83.76, inclusive.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.77 to $84.73, inclusive.
- F5The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.915 to $85.67, inclusive.
- F6100% of the shares subject to this option are fully vested and exercisable.